Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AEterna Zentaris Inc Submits New Drug Application to FDA for Macimorelin Acetate (AEZS-130) for Evaluation of AGHD


Tuesday, 5 Nov 2013 07:30am EST 

Aeterna Zentaris Inc announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency, with accuracy comparable to available intravenous and intramuscular testing procedures. 

Company Quote

1.3
-0.03 -2.26%
1:24pm EDT